Masahiro Shinoda

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi, Masaya Hibino, Ryota Hase et al. · Antimicrobial Agents and Chemotherapy · 2020 · 231 citations · Full text

Open-label Trial, Late Favipiravir Therapy, Clinical Infectious Disease +14

NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese

Nobuyuki Hamajima, Keitaro Matsuo, Hiroji Iwata et al. · International Journal of Clinical Oncology · 2002 · 111 citations

Cancer Risk, Genetics, Quinone Oxidoreductase 1 +9

Lateral and axial deformation of PP, HDPE and PET geogrids under tensile load

Masahiro Shinoda, Richard J. Bathurst · Geotextiles and Geomembranes · 2004 · 96 citations

Geotechnical Engineering, Pet Geogrids, Engineering +9